Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Supernus Pharmaceuticals has selected electronic data capture (EDC) clinical trial software provider DSG to support two phase 3 clinical studies on impulsive aggression in pediatric patients being treated for attention deficit/hyperactivity disorder (ADHD).
Subscribe to our email newsletter
DSG will deliver a fully supported eCaseLink EDC system, including IWRS Web-based randomization-clinical supply, a central lab and third-party CRO data integration, and data management services.
The move will enable Supernus to reduce clinical trial time, decrease trial cost, and enhance trial accuracy.
Through eCaseLink IWRS, Supernus can manage randomization, subject enrollment, and drug supply in its clinical trial.
DSG will run all aspects of clinical study data management from database setup through lock.
DSG CEO Tony Varano said: "We look forward to helping Supernus advance the treatment of central nervous system diseases through the use of embedded and transformational applications.
"This is further evidence that our eClinical solutions are not only leading from a technology perspective, but that our people, processes and product delivery remain the most highly trusted in the industry."
Supernus Pharmaceuticals is engaged in the development and commercialization of products to treat central nervous system diseases.
The company has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
The company is also developing other product candidates including SPN-810 to treat impulsive aggression in ADHD patients. SPN-812 is being developed for treatment of ADHD.